SCHEMBL1483403

SCHEMBL1483403

COC(=O)c1ccc(C(=O)O)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.55
KDM4E B2RXH2 3/20 0.50
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
GLA P06280 1/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ABL1 P00519 1/20 0.49
SRD5A2 P31213 2/20 0.47
PYGL P06737 4/20 0.47
KDM6B O15054 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
TPMT P51580 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29606273 1.00 TSHR (0.55) TSHRKDM4EMAPTALDH1A1GLA
SCHEMBL69263 0.89 KDM4E (0.62) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL2890548 0.87 KDM4E (0.51) TSHRKDM4EMAPTALDH1A1GLA
SCHEMBL4657653 0.86 MEN1 (0.56) TSHRKDM4EMAPTALDH1A1GLA
SCHEMBL16957205 0.86 KDM4E (0.50) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL6243384 0.86 KDM4E (0.50) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL3116280 0.86 MAPT (0.50) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL1017792 0.86 KDM4E (0.54) TSHRKDM4EMAPTALDH1A1GLA
SCHEMBL5058881 0.84 HPGD (0.53) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL29699657 0.83 KDM4E (0.55) TSHRKDM4EMAPTALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122212-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
US-20240025923-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS INC (US) 2024-01-25 US disclosed
US-11739101-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof NURIX THERAPEUTICS, INC. (US) 2023-08-29 US disclosed
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
EP-4146660-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2023-03-15 EP disclosed
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-29 US disclosed
US-20220127258-A1 AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) 2022-04-28 US disclosed
EP-3919489-A1 AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The National Institutes of Pharmaceutical R&D Co., Ltd (CN) 2021-12-08 EP disclosed
US-20210355140-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF GILEAD SCIENCES, INC. 2021-11-18 US disclosed
WO-2021226262-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed
US-6229011-B1 BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE HOFFMAN-LA ROCHE INC. 2001-05-08 US disclosed
CN-1288457-A Inhibitors of & alpha, 4 mediated cell adhesion TANABE SEIYAKU CO (JP) 2001-03-21 CN disclosed
CN-1281430-A N-alkanoylphenylalanine derivatives HOFFMANN LA ROCHE (CH) 2001-01-24 CN disclosed
EP-1049662-A1 INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2000-11-08 EP disclosed
EP-1005445-A1 N-ALKANOYLPHENYLALANINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-07 EP disclosed
WO-2000021920-A1 DIAMINOPROPIONIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-04-20 WO disclosed
WO-1999036393-A1 INHIBITORS OF α4 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 1999-07-22 WO disclosed
WO-1999010312-A1 N-ALKANOYLPHENYLALANINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1999-03-04 WO disclosed
EP-0314126-A2 Process and intermediates for the preparation of halogenated protease inhibitors G.D. Searle & Co. (US) 1989-05-03 EP disclosed
US-4803294-A Process and intermediates for the preparation of halogenated protease inhibitors G. D. SEARLE & CO. (US) 1989-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 TSHR 3073/4885KDM4E 3779/4885MAPT 4656/4885
US-11739101-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof TTK, HIPK1, HIPK2 TSHR 4150/4885KDM4E 1247/4885MAPT 2775/4885
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF ITGB1, ITGB2, ITGA2 TSHR 3073/4885KDM4E 3779/4885MAPT 4656/4885
US-20210355140-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, HIPK2 TSHR 4150/4885KDM4E 1247/4885MAPT 2775/4885
US-20250122212-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 TSHR 4462/4885KDM4E 3515/4885MAPT 2531/4885
US-20240025923-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, HIPK2 TSHR 4150/4885KDM4E 1247/4885MAPT 2775/4885
US-20220127258-A1 AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF CYP46A1, NR1H4, CYP7A1 TSHR 2000/4885KDM4E 3794/4885MAPT 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.